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Optic neuritis associated with multiple sclerosis has a strong association with organ-speciﬁc autoimmune disease. The goal of
our research is to establish an optimal organ-speciﬁc animal model to elucidate the pathogenetic mechanisms of the disease and
to develop therapeutic strategies using the model. This paper is divided into ﬁve sections: (1) clinical picture of optic neuritis
associated with multiple sclerosis, (2) elucidation of pathogenesis using animal models with inﬂammation in optic nerve and
spinal cord, (3) clinical relevance of concurrent encephalomyelitis in optic neuritis model, (4) retinal damage in a concurrent
multiple sclerosis and optic neuritis model, and (5) development of novel therapies using mouse optic neuritis model. Advanced
therapies using biologicals have succeeded to control intractable optic neuritis in animal models. This may ultimately lead to
prevention of vision loss within a short period from acute onset of optic neuritis in human. By conducting research ﬂexibly, ready
to switch from the bench to the bedside and from the bedside to the bench as the opportunity arises, this strategy may help to
guide the research of optic neuritis in the right direction.
1.Introduction
When ocular inﬂammation involves other connecting
intraocular or extraocular tissues, the name of the disease
changesdependingonthesiteofinﬂammation.Forexample,
the diagnosis of the disease may vary from conjunctivitis,
scleritis, uveitis (intraocular inﬂammation), chorioretinitis,
to optic neuritis. Ocular inﬂammation usually has an
i n f e c t i o u so ra u t o i m m u n ee t i o l o g y .W h e nt h ec a u s ei s
autoimmunity,inﬂammationusuallyinvolvesspeciﬁcorgans
ortissues.Ourgrouphastakenakeeninterestonthestudyof
optic neuritis associated with multiple sclerosis, which is an
intractable organ-speciﬁc inﬂammatory disease unrespon-
sive to conventional treatments and consequently has a poor
prognosis. Optic neuritis associated with multiple sclerosis
has strong association with organ-speciﬁc autoimmune
disease. Our research, which aims to establish an optimal
organ-speciﬁc animal model to elucidate the pathogenesis
of the disease and to develop therapeutic strategies using
animal model, will contribute to the understanding of the
pathophysiology of intractable optic neuritis in humans and
ultimately to ameliorate the disease in the future.
Optic neuritis associated with multiple sclerosis may
manifest in two forms: opticospinal multiple sclerosis (OS-
MS) which is accompanied by cerebral lesion associated with
multiple sclerosis and neuromyelitis optica (NMO) which is
usually not accompanied with cerebral lesion. No conclusion
has been reached on whether the two forms are in fact
the same entity. The deﬁnition of NMO is the presence
of optic neuritis together with spinal cord lesion extending
over three or more vertebral segments, but not necessarily
cerebrallesion. The presenceofantibodies againstaquaporin
4 (AQP4) is the most important factor associated with the
pathophysiology of NMO, and it has been closed up recently
[1, 2].
Anti-AQP4 antibody has been shown to react with
AQP4 expressed on astrocytes, inducing complement ﬁxa-
tion reaction and leading to cell death [2]. If we consider
NMO as one type of autoimmune disease, B cells that are
responsible for antibody production and T cells that regulate
cytokines which promote antibody production should play
important roles in the development of NMO. Although
the pathogenesis of multiple sclerosis remains incompletely
understood, some antigens of cerebrospinal origin, such as2 Journal of Biomedicine and Biotechnology
myelin basic protein (MBP), have been proposed to cause
inﬂammation in the brain and spinal cord via some autoim-
mune mechanisms. At cellular level, immunity is acquired
through the following pathway: antigen-antigen presenting
cell-T cell-B cell. This may provide a framework to explain
the clinical picture of multiple sclerosis, an autoimmune
disease. Among these major cellular transmission routes,
(1) the type of antigen, (2) the surface molecules (such
as HLA) expressed on antigen-presenting cells including
macrophages and dendritic cells, and (3) the type of
lymphocytes including T cells and B cells will decide the site
of inﬂammation and the size of the lesion. Each of these will
be discussed as follows. (1) Concerning the types of protein
antigen,thecandidatesincludeMBP,myelinoligodendrocyte
glycoprotein (MOG), and the myelin-speciﬁc proteolipid
protein (PLP). Among these proteins, MOG antigen has a
high possibility of causing optic neuritis. MOG has been
shown to be present abundantly inside the optic nerve, and
inﬂammatory cells presumably react to the MOG antigen
of the optic nerve to cause tissue damage [3]. In contrast,
MBP is present abundantly inside the brain and spinal
cord, and it has been suggested that optic neuritis rarely
develops in the presence of MBP-induced encephalomyelitis.
Therefore, the site of lesion is determined depending on
which antigen is targeted by the immune system. (2) As for
the involvement of antigen-presenting cells, classic multiple
sclerosis has been associated with the expression of HLA-
DR2 on antigen-presenting cells. In addition, the state of
adhesion molecules expressed on antigen-presenting cells
is a factor that attenuates inﬂammation. (3) Regarding the
involvement of T cellsand B cells, an increase in Th17-type T
cells producing IFN-γ and IL-17, as well as an accumulation
of B cells that are precursors of the antibody-producing
plasma cells have been suggested in optic neuritis associated
with multiple sclerosis. In severe NMO cases in which the
above-mentioned anti-AQP4 antibody was detected, apart
from the autoimmune mechanisms, the antibody per se also
causes direct cell damage (astroglia in this case), which may
account for the higher incidence of severe damage compared
to OS-MS. From the immunological point of view, it may
be possible to classify anti-AQP4 antibody-positive NMO
withinthecategoryofOS-MS,withtheanti-AQP4antibody-
negative OS-MS classiﬁed as a mild type with little antibody-
induced tissue damage. The feasibility of this classiﬁcation
can only be veriﬁed in a large scale of clinical study regarding
NMO.
2.ElucidationofPathogenetic Mechanisms
Using Animal Models with Inﬂammations in
OpticN e rv eandSpinalC o r d
As discussed above, immunological mechanisms are con-
sidered to play a role in optic neuritis associated with
multiple sclerosis. However, this hypothesis can only be
proven when one demonstrates the development of speciﬁc
lesion by adjuvant immunizing the host with the causative
protein antigen. So far, research analyzing the optic nerve
lesion using animal models of multiple sclerosis has not
been conducted actively. In the 1990s when experimental
autoimmune encephalomyelitis (EAE), which is an animal
model of multiple sclerosis, was being developed, a study
reported that immunizing mice with the central nervous
system- (CNS-) speciﬁc PLP resulted in the onset of optic
neuritis on day 17 after immunization [4]. Histopathological
examination of the optic nerve showed inﬁltration of
polymorphonuclear cells and monocytes [4], resembling the
ﬁndings of optic neuritis associated with multiple sclerosis
in human. Likewise, another CNS protein MOG, when used
to immunize Brown Norway (BN) rats, also caused optic
neuritis within 3 weeks in 90% of the animals, in addition to
encephalomyelitis [5]. These studies provide clear evidence
that in certain strains of rodents, optic neuritis develops as a
result of immunization with antigens derived from neuron.
However,eveninratsandmice,theMHCtypes(haplotypes)
in which optic neuritis can develop are probably restricted, a
phenomenon probably similar to the increased susceptibility
of HLA-DR2-positive human to multiple sclerosis.
In the mouse model that develops both encephalomyeli-
tis and optic neuritis, the onset of encephalomyelitis
is usually observed 13 days on average after adjuvant-
immunization with the MOG35-55 peptide. However, when
T cells obtained from these mice are injected intraperi-
toneally (adoptive immunization) to normal mice, optic
neuritisalsodevelopsinthesemice[6].Thisﬁndingindicates
that the T cells possessing the pathogenetic factor of optic
neuritis are important in the development of autoimmune
optic neuritis. As an evidence that these MOG-speciﬁc T
cells are an important pathogenetic factor, transgenic mice
possessing T cells with MOG35-55-speciﬁc T cell receptor
(TCR)developedopticneuritisspontaneously,withaclinical
course resembling that of multiple sclerosis in humans,
which is an interesting observation [7]. Furthermore, when
these MOG-speciﬁc TCR transgenic mice were crossed with
MOG-speciﬁc Ig heavy-chain (closely associated with B
cells) knock-in mice, the incidence of spontaneous optic
neuritis increased markedly [8]. As a possible mechanism,
Bettelli et al. [8] proposed that IL-17- and IFN-γ-producing
CD4+ T cells are involved in the development of optic
neuritis in mice. The IL-17-secreting Th17 cells possess
unique properties diﬀerent from those of Th1 cells that
are closely associated with the development of EAE and
experimentalautoimmuneuveoretinitis(ananimalmodelof
human uveitis), and those of Th2 cells that are involved in
allergic diseases. IL-17 has been considered as an important
cytokine for the development of autoimmune diseases.
Taken together, the following hypothesis may be proposed.
Through the action of the newly discovered Th17 mecha-
nism, but not Th1 or Th2, the T cells, IgH-producing B
cells, and antigen that causes CNS lesion interact to produce
the pathophysiology of mouse encephalomyelitis and optic
neuritis.
Oligodendrocyte-speciﬁc protein- (OSP-) induced EAE
is a relatively new model of multiple sclerosis, and similar
ﬁndings have been reported by other institutes. OSP is a
protein present in the myelin sheath of the CNS. Mice
immunized with OSP develop optic neuritis together with
encephalomyelitis [9]. Study has shown that OSP55-80 andJournal of Biomedicine and Biotechnology 3
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Figure 1: Histopathological ﬁndings of the optic nerve from
a mouse adjuvant immunized with MOG peptide. Marked cell
inﬁltration is observed in the optic nerve.
OSP179-207 derived from the OSP molecule are epitopes
recognized by CD4+ T cells that mediate lesion formation. In
addition,theantibodiesinducedbyOSPwerepredominantly
directed against OSP22-46 [9]. These ﬁndings suggest that
T cells and B cells collaborate in an antigen-speciﬁc manner
to give rise to the clinicopathological manifestations of this
model.
From these studies, the pathogenesis of multiple sclerosis
and the associated optic neuritis become gradually unrav-
eled. However, the incidence of optic neuritis in mouse
models has stayed at 60% to 70%, even when gene transfer
technology is used. In order to be used in therapeutic
experimentsinthefuture,ahigherincidenceofopticneuritis
of the animal model has to be achieved. By mixing dimethyl
sulfoxide(DMSO)duringimmunizationwithMOGpeptide,
we have successfully increased the incidence of optic neuritis
from 80% to 90% in mice (report in preparation). The
histopathologicalpictureofopticneuritisobtainedusingthis
animal model is shown in Figure 1, and the Luxol myelin
sheath staining of optic neuritis is shown in Figure 2.I n
the section stained by Luxol fast blue for myelin sheath,
unstained regions indicating destruction of the myelin
sheath were consistent with areas of cell inﬁltration. In an
in vitro experiment, spleen cells collected from a mouse that
developed optic neuritis were cultured, and the cytokines in
the culture supernatant were assayed. IL-17 level was high,
and IFN-γ was slightly elevated in the supernatant. On the
other hand, secretion of IL-10, an inhibitory cytokine, was
notremarkable.Theseresultsconﬁrmpreviouscytokinedata
of mouse optic neuritis model and probably predict the
results of analysis of optic neuritis in human.
3.ClinicalRelevance of Concurrent
Encephalomyelitis inOpticNeuritis Model
When experimental autoimmune optic neuritis (EAON) is
produced, EAE occurs at the same time. EAE is known
to be a model of human multiple sclerosis. Regarding the
relationship between EAE and multiple sclerosis, although
the two share many common features histopathologically,
they also diﬀer in many aspects which remain unclariﬁed.
When we try to analyze EAON, the interpretation of EAE,
which has been extensively studied, is important.
In the EAE animal model, MOG protein is considered
to be the major causative antigen. In humans, approximately
50% of multiple sclerosis patients are positive for anti-MOG
antibody, while an equal number of patients are negative.
Recently, a tetramer radioimmunoassay has been developed,
which is more sensitive than the conventional technique
such as ELISA and ﬂow cytometric assays. This radioim-
munoassayiscapableofdetectingconformationaldiﬀerences
in MOG protein and allows discrimination between native
MOG (or folded MOG) and denatured MOG (or unfolded
MOG). Human study using this method has demonstrated
that antibodies from adult-onset multiple sclerosis do not
bind native MOG while antibodies from children with acute
disseminated encephalomyelitis (ADEM) react with native
MOG. On the other hand, adult-onset multiple sclerosis
cases react immunologically with denatured MOG [10]. In
animal study using this method, antibodies from EAE do not
bind native MOG [10].
It remains unknown whether native MOG or denatured
MOG is the main target protein in autoimmune optic
neuritis or NMO. If one can establish that the antibodies
fromopticneuritis-relateddiseasesrecognizeaconﬁguration
of the MOG protein diﬀerent from that recognized by
antibodies from general multiple sclerosis (e.g., antibodies of
patients with ADEM that recognize native MOG), this will
provide evidence that optic neuritis and multiple sclerosis
are independent diseases. Further analyses are expected to
generate interesting new insights.
4. Retinal Damage inaConcurrentMultiple
SclerosisandOptic NeuritisAnimalModel
In an animal model of multiple sclerosis, retinal ganglion
cells are also damaged, although this ﬁnding has not
been proven in humans. Meyer et al. [11] reported that
encephalomyelitis developed in rats after immunization with
MOG, inﬂammation occurred in the optic nerve axons, and
apoptosis of retinal ganglion cells was induced. These results
are very interesting, because it is generally believed that
peripheralnerveswithoutamyelinsheatharenotattackedin
multiplesclerosis.Infact,peripheralnerveﬁbersintheretina
are not directly damaged in patients with multiple sclerosis.
Likewise, a study using MOG-speciﬁc TCR transgenic mice
showed that optic neuritis occurred spontaneously and
retinal ganglion cells were gradually damaged starting from
day 12, with TUNEL-positive apoptotic cells increasing
to 83% on day 16 [12]. Therefore, in animal models of
multiple sclerosis, retinal ganglion cells may be concurrently
damaged, and the involvement of IL-1β and glial cell
line-derived neurotrophic factor in neurodegeneration has
attracted interest [13]. These molecules are probably related
to neuroprotection. Future studies using optical coherence4 Journal of Biomedicine and Biotechnology
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Figure 2: Luxol fast blue staining for myelin sheath in the optic
nerve of a mouse adjuvant immunized with MOG peptide. Regions
of weak staining of the myelin sheath corresponds to regions of cell
inﬁltration in the optic nerve.
tomography (OCT) to analyze the perioptic nerve retina
in multiple sclerosis patients may provide proof of retinal
ganglion cell damage in humans.
5.Development of Novel Therapies Using
MouseOpticNeuritisModel
Recently, progress in the elucidation of the pathogenesis
of intractable optic neuritis has reached a level that allows
application of the research ﬁndings to treatment clinically.
Obviously animal models are indispensable for the research
and development of therapeutic modalities. Gene therapy
has been attempted using animal model of optic neuritis.
Guy et al. [14, 15] injected an adenovirus vector containing
the human gene for catalase (possessing antioxidant activity)
over the optic nerve head of mice with EAE and succeeded
to suppress optic neuritis together with encephalomyelitis
in these mice. Furthermore, by injecting an adenovirus
vector containing both catalase and extracellular superoxide
dismutase (ECSOD) genes (dual gene therapy) into the
eye of EAE models, demyelination was attenuated [16, 17].
Moreover, gene therapy using another antioxidant gene,
superoxide dismutase 2 (SOD2), also suppressed mitochon-
drial oxidative stress and ameliorated the optic neuritis and
encephalomyelitis in a mouse model [18].
Our group is currently conducting trials to suppress
optic neuritis in mice using an approach entirely dif-
ferent from those reported hitherto. It is known that
a speciﬁc immunoregulatory mechanism termed anterior
chamber-associated immune deviation (ACAID) is present
in the eye to maintain immune privilege in the intraoc-
ular environment [19]. This unique immunoregulatory
mechanism in the anterior chamber maintains humoral
immunity including serum antibody production, but sup-
presses cell-mediated immunity represented by intradermal
reaction. Immunosuppressive substances such as TGF-ß
and neuropeptides present in the anterior chamber play
important roles in the ACAID phenomena. Inside the
anterior chamber which is an immune privilege site, cells
including macrophages are stimulated by antigen in the
presence of immunoregulatory substances, and subsequently
come into contact with T cells; these T cells migrate out
of the eye and are transformed into regulatory T cells.
We have examined the possibility of suppressing optic
neuritis using the ACAID immunoregulatory system [20],
and we found that the incidence was reduced to 70% in the
group that received injection of MOG peptide antigen into
the anterior chamber while 100% of mice in the positive
control group developed optic neuritis. When the severity
of optic neuritis was compared by histopathological scores,
the anterior chamber injected group which was markedly
reduced compared to the positive control group. These
results prove that the ACAID immunoregulation is eﬀective
in controlling optic neuritis. The salient point about this
immunoregulatory system is that disease development is
mediated by the host’s own immunoregulatory cells. We
thus prepared immunoregulatory cells by transferring the
calcitonin gene-related peptide (CGRP, known as a neu-
ropeptide) gene into dendritic cells isolated from a mouse.
Intravenous injection of the gene-transferred cells into the
same mouse ameliorated optic neuritis that developed in the
EAE model (report under preparation). This experimental
study indicates the possibility to ameliorate optic neuritis by
autologous cell therapy.
6. Conclusion
Research to elucidate the pathogenetic mechanism of
intractable optic neuritis has shown great progress in recent
years, both clinically and also in experimental models.
Some of these study results have begun to reach a level
permitting their application to analyses of the patho-
physiology of human optic neuritis and development of
treatment clinically. If cell-mediated therapy, gene therapy,
and other advanced therapies using biologicals succeed to
control intractable optic neuritis in animal models, this may
ultimately lead to prevention of vision loss of optic neuritis
in humans. By conducting research ﬂexibly, ready to switch
from the bench to the bedside and from the bedside to the
bench as the opportunity arises, this strategy may help to
guide the research of optic neuritis in the right direction.
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